Business
Red Thread Ventures' portfolio company Rakovina Therapeutics'
Red Thread Ventures' portfolio company Rakovina Therapeutics' Canada NewsWire ...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"\n \n \n \n Red Thread Ventures' portfolio company Rakovina Therapeutics'\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n DDR-inhibitors Exploit Cancer's \"Achilles' Heel\"\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n Aug. 11, 2021\n \n /CNW/ - At the Emerging Growth Conference on\n \n June 23, 2021\n \n , Rakovina Therapeutics (TSXV: RKV) (\"the Company\") gave an insightful rundown of their company and their cancer fighting strategy.\n \n \n Rakovina Therapeutics is a\n \n Vancouver\n \n -based biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response inhibitor (DDRi) technologies. \"Rakovina is dedicated to developing innovative treatments with the potential to improve patient outcomes across many different types of cancer,\" noted\n \n Jeffrey Bacha\n \n , Rakovina Therapeutics' executive chairman.\n \n \n Our cells incur tens of thousands of DNA damaging events daily. The DNA damage response acts as a protector in that it detects and repairs these natural events. \"As we've come to understand, certain types of cancer take advantage of a defect in one or more of these systems allowing a mutation to sneak through and become ingrained in the cell.  If this mutation is associated with cellular growth, a tumour will form, and the patient will eventually be diagnosed with cancer.\" stated Bacha.\n \n \n Mr. Bacha further explained that because the DDR-associated mutation is found only in the cancer cells and not in normal cells, it provides an opportunity for targeted therapies. These therapies generate specific lethality to the tumour while sparing normal cells, thereby reducing side effects.\n \n \n Four FDA-approved DDR inhibitors, called PARP=inhibitors, have been launched in recent years. They have become integral in the treatment of several tumors including breast, ovarian and prostate cancer.\n \n \n As a leading cause of death worldwide, cancer was the cause of over 10 million deaths in 2020. This statistic only continues to persevere ...